Krystexxa FDA Approval History
FDA Approved: Yes (First approved September 14, 2010)
Brand name: Krystexxa
Generic name: pegloticase
Dosage form: Injection
Company: Savient Pharmaceuticals, Inc.
Treatment for: Gout
Krystexxa (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.
Development timeline for Krystexxa
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.